Last reviewed 2026-04-22 · How we verify

Avastin®, paclitaxel, carboplatin

Avastin®, paclitaxel, carboplatin is a Anti-angiogenic monoclonal antibody + chemotherapy combination Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Breast cancer.

This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells.

This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells. Used for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Breast cancer.

At a glance

Mechanism of action

Bevacizumab (Avastin) is a monoclonal antibody that blocks VEGF signaling to prevent new blood vessel formation in tumors, starving them of nutrients. Paclitaxel is a microtubule stabilizer that disrupts cell division, while carboplatin is a platinum-based alkylating agent that damages DNA. Together, this triplet regimen combines anti-angiogenic and cytotoxic mechanisms for enhanced anti-tumor activity.

Approved indications

• Advanced or metastatic non-small cell lung cancer
• Ovarian cancer
• Breast cancer

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Peripheral neuropathy
• Hypertension
• Proteinuria
• Nausea and vomiting
• Alopecia

Key clinical trials

• A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
• Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) (PHASE3)
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (PHASE1)
• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) (PHASE3)
• Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (PHASE2)
• PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . (PHASE2)
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Avastin®, paclitaxel, carboplatin CI brief — competitive landscape report
• Avastin®, paclitaxel, carboplatin updates RSS · CI watch RSS
• Jiangsu HengRui Medicine Co., Ltd. portfolio CI

Frequently asked questions about Avastin®, paclitaxel, carboplatin

Related

• Drug class: All Anti-angiogenic monoclonal antibody + chemotherapy combination drugs
• Target: All drugs targeting VEGF (bevacizumab); tubulin (paclitaxel); DNA (carboplatin)
• Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Advanced or metastatic non-small cell lung cancer
• Indication: Drugs for Ovarian cancer
• Indication: Drugs for Breast cancer